Sareum Holdings PLC (GB:SAR)
LSE:SAR
Want to see GB:SAR full AI Analyst Report?
SAR Stock Chart & Stats
15.00 p
0.10 p(0.44%)
At close: 4:00 PM EST
15.00 p
0.10 p(0.44%)
Day’s Range― - ―
52-Week Range9.50 p - 29.00 p
Previous CloseN/A
Volume41.80K
Average Volume (3M)619.72K
Market Cap
£28.30M
Enterprise Value25.82M
Total Cash (Recent Filing)£2.49M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.02
Next Earnings
Oct 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding138,065,170
10 Day Avg. Volume1,134,615
30 Day Avg. Volume619,716
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)8.68
Price to Sales (P/S)0.00
P/FCF Ratio-7.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)£43.15M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free balance sheet materially lowers fixed financing costs and reduces bankruptcy risk for an early-stage biotech. This structural strength gives management optionality to time licensing or partnering deals, supports continued R&D spend without interest burden, and improves resilience across funding cycles.
Partnering/licensing Business ModelA focus on discovery with monetization through partnerships and licensing aligns capital intensity with external resources, reducing the need to build commercial infrastructure. This durable model enables value realization via milestones and royalties, leverages larger partners for late-stage development, and limits fixed operating scale.
Narrowing Cash Outflow TrendA reduction in cash outflow signals improving operational discipline or reprioritization of R&D spend, which can extend runway without immediate dilution. If sustained, this trend strengthens the company's ability to reach partnership milestones, negotiate better deals, and manage funding timing across the next several quarters.
Bears Say
Pre-revenue OperationsBeing effectively pre-revenue is a persistent structural constraint: the business must rely on external financing or partner deals to fund R&D. Without recurring sales, the company faces ongoing dilution and limited internal cash generation, extending the timeline and execution risk to reach commercial sustainability.
Sustained Cash BurnConsistent negative operating and free cash flow creates structural funding pressure and increases dependency on equity or partnership milestones. Persistent cash burn elevates dilution risk, constrains long-term planning, and can force asset-light tradeoffs that slow development if new non-dilutive financing is not secured.
Small, Volatile Equity And Negative ROEVolatile and limited equity capital combined with negative ROE undermines balance sheet resilience. This structural weakness reduces buffer against development setbacks, can complicate negotiations with partners or lenders, and raises the probability that future capital raises will be required under potentially dilutive or unfavorable terms.
Sareum Holdings News
SAR FAQ
What was Sareum Holdings PLC’s price range in the past 12 months?
Sareum Holdings PLC lowest share price was 9.50 p and its highest was 29.00 p in the past 12 months.
What is Sareum Holdings PLC’s market cap?
Sareum Holdings PLC’s market cap is £28.30M.
When is Sareum Holdings PLC’s upcoming earnings report date?
Sareum Holdings PLC’s upcoming earnings report date is Oct 26, 2026 which is in 182 days.
How were Sareum Holdings PLC’s earnings last quarter?
Sareum Holdings PLC released its earnings results on Mar 12, 2026. The company reported -0.012 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.012 p.
Is Sareum Holdings PLC overvalued?
According to Wall Street analysts Sareum Holdings PLC’s price is currently Overvalued.
Does Sareum Holdings PLC pay dividends?
Sareum Holdings PLC does not currently pay dividends.
What is Sareum Holdings PLC’s EPS estimate?
Sareum Holdings PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sareum Holdings PLC have?
Sareum Holdings PLC has 138,065,170 shares outstanding.
What happened to Sareum Holdings PLC’s price movement after its last earnings report?
Sareum Holdings PLC reported an EPS of -0.012 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.143%.
Which hedge fund is a major shareholder of Sareum Holdings PLC?
Currently, no hedge funds are holding shares in GB:SAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sareum Holdings PLC
Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.
Technical Analysis
ImmuPharma
―
Fusion Antibodies Plc
―
Poolbeg Pharma Ltd.
―
Arecor Therapeutics PLC
―
Aptamer Group Plc
―